Yes, metoprolol can cause erectile dysfunction, and the effect is more common than most prescribers mention. Among men taking beta-blockers, roughly 10 to 15 percent report new or worsening erectile dysfunction, and metoprolol's label lists it as an adverse reaction reported during post-marketing use. The problem is usually dose-related and partial rather than total: many men notice weaker rigidity or harder maintenance of an erection rather than complete loss. The effect is broadly reversible, and switching to certain other blood pressure medicines often restores function within weeks to a few months.
Why Metoprolol Interferes With Erection Physiology
An erection is a hydraulic event controlled by two opposing nervous systems. The parasympathetic branch releases nitric oxide, which relaxes the smooth muscle inside the penile arteries and lets roughly 100 to 130 milliliters of blood flood the corpus cavernosum. The sympathetic branch does the opposite: it keeps that smooth muscle contracted and enforces flaccidity between erections.
Metoprolol is a cardioselective beta-1 antagonist. Its job is to block adrenaline and noradrenaline at the heart, slowing rate and lowering pressure. The selectivity is dose-dependent, though. At low doses, roughly 50 to 100 milligrams daily of the tartrate formulation, it binds mostly beta-1 receptors. As the dose climbs past 150 to 200 milligrams, or with the extended-release succinate formulation, it begins blocking beta-2 receptors in blood vessels and cavernosal tissue as well.
Here is the non-obvious part most explainers miss: the erectile problem is not fully explained by blood pressure lowering. Beta-2 receptors in penile tissue participate in vasodilation, and their blockade removes a secondary relaxation pathway. Blockade also leaves alpha-adrenergic tone unopposed at the cavernosal smooth muscle, tilting the balance toward flaccidity. In plain terms: metoprolol does not just lower the pressure pushing blood in; it slightly strengthens the signal that keeps blood out.
There is a third mechanism, and it is psychological rather than vascular. Fatigue and reduced exercise tolerance are common beta-blocker side effects. A man who feels flat and sluggish is less likely to initiate sex and more likely to interpret a single weak erection as permanent failure. Performance anxiety then recruits the sympathetic nervous system, which is precisely the wrong branch for erection. The loop becomes self-sustaining.
Metoprolol also does not raise prolactin or crash testosterone the way some other drug classes do. Its mechanism is neurovascular and hemodynamic, not hormonal. That distinction matters because it predicts reversibility: nothing structural is being damaged.
How Common Is Beta-Blocker ED, and How Does Metoprolol Compare?
The best-known number comes from the Treatment of Mild Hypertension Study, published in 1993, which followed men on five different first-line regimens. Erectile dysfunction was reported by roughly 9 to 11 percent of men on the beta-blocker (chlorthalidone and doxazosin arms had lower rates). Broader reviews of beta-blockers place the pooled incidence between 10 and 15 percent, with wide variation by drug, dose, and how the question is asked.
Most of those historical numbers come from older, non-selective agents such as propranolol. Metoprolol sits in an intermediate position: more selective than propranolol, less selective than nebivolol, which has additional nitric-oxide-mediated vasodilating properties and consistently shows the lowest ED rates in head-to-head work.
| Drug | Class | Reported ED rate | Key mechanistic note |
|---|---|---|---|
| Metoprolol tartrate | Cardioselective beta-1 | ~10-15% | Selectivity fades above 150-200 mg/day |
| Metoprolol succinate | Cardioselective beta-1 (ER) | ~10-15% | Smoother levels, similar risk |
| Atenolol | Cardioselective beta-1 | ~10-13% | Renal clearance, similar profile |
| Propranolol | Non-selective | ~15-20% | Blocks beta-2 at all doses |
| Nebivolol | Beta-1 selective + NO-mediated | ~3-5% | Vasodilating, lowest reported ED rates |
| Placebo | — | ~4-10% | Baseline rate in trial populations |
The placebo column is the corrective most articles skip. In hypertension trials, 4 to 10 percent of men on placebo report erectile dysfunction, largely because high blood pressure itself damages the small vessels feeding the penis. Knowing the baseline keeps a 12 percent metoprolol rate in perspective: it may represent a true excess of only 3 to 7 percentage points.
That said, a 2024 analysis of FDA adverse event reporting data found beta-blockers over-represented among cardiovascular drugs associated with sexual dysfunction reports. Signal detection is not proof of causation, but it is consistent with the older trial data.
Dose, Age, and Other Factors That Raise Your Risk
Risk is not uniform across men on metoprolol. Four variables move the probability substantially.
Dose is the strongest. At 25 to 50 milligrams daily, ED reports are close to placebo rates in most series. Risk rises meaningfully above 100 milligrams and climbs again above 200 milligrams. Extended-release succinate at 200 milligrams delivers roughly equivalent exposure to tartrate 200 milligrams split twice daily, so formulation changes the dosing convenience more than the receptor profile at matched total daily doses.
Age compounds the issue. Erectile dysfunction prevalence in the general male population is roughly 5 percent at age 40 but approaches 40 to 50 percent by age 70, per long-running Massachusetts Male Aging Study data. A 55-year-old starting metoprolol has far more baseline vascular compromise than a 35-year-old, and the drug's marginal contribution is easier to see in the younger man.
Comorbidities matter enormously. Diabetes roughly doubles ED risk on its own. Smoking, untreated sleep apnea, and depression each independently impair erectile function. When several stack on top of a beta-blocker, the drug may be the lightest straw rather than the heaviest.
Finally, duration. Most drug-induced ED emerges within the first 4 to 12 weeks of therapy or after a dose increase. If function was normal for two years on a stable metoprolol dose and then declined, the drug is unlikely to be the primary cause, and other explanations deserve a workup.
When Symptoms Appear: What to Expect on Metoprolol
The timing of symptoms helps distinguish drug effect from other causes. Most men notice changes in a predictable window after starting or escalating therapy.
| Time since starting or changing dose | What you may notice | Interpretation |
|---|---|---|
| Day 1-3 | Mild fatigue, no sexual change expected | Too early for vascular effects |
| Week 1-2 | Lower libido, occasional weaker erection | Possible early drug effect or fatigue |
| Week 3-8 | Consistent weaker rigidity or maintenance issues | Typical window for drug-related ED |
| Week 8-12 | Stable reduced function at fixed dose | Drug effect likely plateaued |
| Month 3-6 | Slow improvement without dose change | Suggests tolerance or psychological adaptation |
| 2-6 weeks after stopping or switching | Partial to full return of function | Strongly supports drug causation |
| 3-6 months after switching | Function typically back to baseline | Reversibility window closes |
The 2-to-6-week recovery after discontinuation is the single most useful diagnostic clue. It is not a formal test, but it is the observation that most reliably separates drug effect from coincidental vascular decline.
What Men and Clinicians Often Get Wrong
The most common misconception is that metoprolol is a uniquely bad choice. It is not. Non-selective beta-blockers such as propranolol carry higher reported ED rates, and the class effect is broad. The real question is whether a given patient needs a beta-blocker at all, and if so, which one.
A second misconception is that lowering the dose solves everything. Dose reduction helps, but only if the reduction preserves blood pressure control. Dropping from 100 to 50 milligrams may restore function in some men while losing the antihypertensive benefit. Tapering rather than stopping abruptly is mandatory because of rebound tachycardia and angina risk.
A third, more subtle error is assuming the culprit is the beta-blocker when it is actually a thiazide or a statin added at the same visit. Thiazides, spironolactone, and many antidepressants carry their own ED signals. A careful medication timeline, not a guess, identifies the actual offender.
A professional caveat worth stating plainly: the literature on metoprolol-specific ED is thinner than on propranolol, and much of the class-level risk estimate is extrapolated. The label warning is based on post-marketing reports, which are voluntary and subject to reporting bias. In plain terms: the risk is real, but the exact percentage for metoprolol specifically is less certain than the headline number implies.
Practical Steps: What to Actually Do About It
If you suspect metoprolol is affecting your erections, the response should not be to stop the drug yourself. Abrupt cessation can trigger rebound hypertension or, in men with coronary disease, angina and arrhythmia.
- Track it in writing. Record the date metoprolol started, any dose changes, and when symptoms emerged. A simple two-week log of rigidity, libido, and morning erections gives your clinician something concrete to work with.
- Ask about alternative agents. Nebivolol, carvedilol at low dose, or non-beta-blocker options such as ACE inhibitors, ARBs, or calcium channel blockers may control blood pressure with less sexual impact. This is a swap, not a stop.
- Do not skip doses to test yourself. Irregular dosing produces volatile blood pressure and confounds the picture.
- Rule out the big non-drug causes first. Morning erections, testosterone levels, thyroid function, and sleep apnea screening are inexpensive and frequently reveal the real culprit.
- Address vascular health directly. The same exercise, weight, and smoking changes that help erectile function also help hypertension, and they may allow a lower dose eventually.
- See a clinician promptly if you develop chest pain, a sudden complete loss of erection function, or new symptoms after a dose change. See the bulleted red flags below.
Red flags that warrant urgent medical review: chest pain or pressure after starting metoprolol, a resting pulse below 50 beats per minute, fainting or near-fainting, new shortness of breath with exertion, or a sudden complete inability to maintain any erection when it had been intact within the prior month.
Limits of the Evidence and What Remains Uncertain
Honest uncertainty belongs in any account of this topic. Most of the landmark beta-blocker ED data is three decades old, drawn from trials that used blunt single-question assessments rather than validated instruments such as the International Index of Erectile Function. Modern trials using the IIEF generally report lower absolute rates, partly because the questionnaire is more specific.
Metoprolol-specific randomized data comparing it directly against nebivolol on erectile function are sparse. The nebivolol literature is more robust, and its lower ED rates are consistently replicated, but the comparison base is smaller than the overall beta-blocker class.
Individual variation is real and poorly predicted. Two men on identical 100-milligram succinate doses can have opposite sexual outcomes. Genetics of beta-receptor expression, baseline vascular reserve, and psychological context all play roles that current models cannot fully capture.
What is established: metoprolol can cause erectile dysfunction, the effect is dose-related, the mechanism is neurovascular rather than hormonal, and it is usually reversible. What remains uncertain: the exact metoprolol-specific risk percentage, the degree to which psychological factors amplify the physiological effect, and whether long-term use carries any cumulative risk beyond the first few months. Those questions are answerable with better prospective data, and for now, the practical implication is straightforward: this is a manageable side effect, not a permanent sentence, and it deserves a conversation with the prescriber rather than silent suffering.